First-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Azim, H. A.; El Saghir, N. S.; Yap, Y. S.; Eralp, Y.; Im, S\\-A.; Sandhu, M. S.; Abdel\\-Razeq, H.; Gupta, S.; Artamonova, E.; Rihani, J.; Alfaro, T. Delgar; Wu, J.; Hu, H.; Gao, M.; Lu, Y\\-S.

doi:10.1016/j.annonc.2023.09.579

First-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Tarih

2023

Yazarlar

DOI No

10.1016/j.annonc.2023.09.579

Diğer Tanımlayıcı No

WOS:001087480200391

Yayınevi

ELSEVIER

Özet

Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid, SPAIN, OCT 20-24, 2023

URI

https://openaccess.acibadem.edu.tr/handle/11443/6158

Koleksiyonlar

WOS

Tam öğe sayfası

First-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Tarih

Yazarlar

Süreli Yayın başlığı

Süreli Yayın ISSN

Cilt Başlığı

ISSN

DOI No

Diğer Tanımlayıcı No

Cilt

Sayı

Yayınevi

Özet

Açıklama

Anahtar kelimeler

Alıntı

URI

Koleksiyonlar

Endorsement

Review

Supplemented By

Referenced By